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ORIGINAL ARTICLE
An investigation of the antiplatelet effects of succinobucol (AGI-1067)
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Abstract
Succinobucol is a phenolic antioxidant with anti-inflammatory and antiplatelet effects. Given
the importance of oxidant stress in modulating platelet–platelet and platelet–vessel wall
interactions, the aim of this study was to establish if antioxidant activity was responsible for
the antiplatelet activity of succinobucol. Platelet aggregation in response to collagen and
adenosine diphosphate (ADP) was studied in rabbit whole blood and platelet-rich plasma
using impedance aggregometry. The effect of oxidant stress on aggregation, platelet lipid
peroxides, and vascular tone was studied by incubating platelets, washed platelets or pre-
constricted rabbit iliac artery rings respectively with a combination of xanthine and xanthine
oxidase (X/XO). To study the effect of succinobucol in vivo, anaesthetized rats were injected
with up to 150 mg/kg succinobucol and aggregation measured in blood removed 15 mins
later. Succinobucol (10−5–10−4 M) significantly attenuated platelet aggregation to collagen and
ADP in whole blood and platelet-rich plasma. X/XO significantly increased aggregation to
collagen and platelet lipid peroxides and this was reversed by succinobucol. Addition of X/
XO to denuded rabbit iliac arteries caused a dose-dependent relaxation which was significantly
inhibited by succinobucol. In vivo administration up to 150 mg/kg had no effect on heart rate
or mean arterial blood pressure but significantly inhibited platelet aggregation to collagen ex
vivo. In conclusion, succinobucol displays anti-platelet activity in rabbit and rat blood and
reverses the increase in platelet aggregation in response to oxidant stress.
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Introduction
Succinobucol [mono[4-[[1-[[3,5-bis(1,1-dimethylethyl)-4-hydro-
xyphenyl]thio]-1-methylethyl]thio]-2,6-bis(1,1-dimethylethyl)
phenyl] ester] (butanedioc acid) is a phenolic antioxidant deriva-
tive of probucol, which has consistently demonstrated improved
pharmacokinetics, antiproliferative, and anti-inflammatory effects
compared with probucol [1–3]. Succinobucol inhibits cytokine
release by monocytes and expression of proinflammatory cell
adhesion molecules by endothelial cells (ECs) [4]. However, it
has not fulfilled early clinical promise due to deleterious changes
in lipid profiles and increased incidence of atrial fibrillation [5].
Our own studies using the pig model of coronary stenting have
demonstrated that a 1% succinobucol-eluting stent actually wor-
sened the extent of neointima formation and vascular inflamma-
tion, possibly due to toxic effects on smooth muscle and ECs
observed in vitro [6]. Despite disappointing clinical results,
experimental studies using derivatized compounds with succino-
bucol as the base molecule are still ongoing with efforts directed
at improving its therapeutic effects [7,8].
Interestingly, succinobucol has demonstrable antiplatelet activ-
ity and in healthy volunteers can reduce aggregation of platelets
to ADP and expression of activation-dependent biomarkers such
as the PAR-1 thrombin receptor [9,10]. In volunteers with multi-
ple risk factors for coronary artery disease (CAD) administration
of 300 mg of succinobucol daily for 12 weeks was sufficient to
reduce generation of thromboxane B2 by platelets without affect-
ing EC prostaglandin production [11]. Since the endothelium is a
key component in preventing platelet aggregation and adhesion, a
lack of effect of succinobucol on the vasodilator and antiaggrega-
tory capacity of the endothelium may be a distinct advantage.
Oxidative stress is widely recognized as contributing to cardi-
ovascular disease progression [12] and can play an important role
in triggering platelet/EC activation. This may be either a direct
effect of oxidant stress on the platelet [13] or an indirect effect
through destruction of labile endothelium-derived vasodilators
such as nitric oxide [14]. However, the direct effects of reactive
oxygen species (ROS) on platelets are inconsistent with previous
studies reporting both pro- and anti-aggregatory effects when
platelets are exposed to exogenous ROS [15]. Oxidant stress
generated either by platelets themselves via several intracellular
sources [16] or by the artery wall can also modulate vascular tone
[17] and this has implications for blood flow and thrombus for-
mation within blood vessels.
Given the importance of oxidative stress in modulating plate-
let–platelet and platelet–vessel wall interactions, we hypothesized
that the antiplatelet effects of succinobucol may be mediated
through free-radical scavenging or protecting the platelet against
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the effects of oxidant stress. In the present study, we aimed to
study the mechanism underlying the antiplatelet effects of succi-
nobucol in vitro and ex vivo.
Materials and methods
Animals
Male New Zealand White (NZW) rabbits and Sprague–Dawley
(SD) rats used in this study were housed at the University of
Glasgow and maintained on 12 hour cycles of light and dark and
at ambient temperature. All procedures conformed to the Guide
for the Care and Use of Laboratory Animals published by the US
National Institutes of Health (NIH Publication No. 85–23, revised
1996) and Directive 2010/63/EU of the European Parliament.
Rabbits (2.5–3 kg) were euthanized by injection of sodium pen-
tobarbital (200 mg/kg) via the marginal ear vein. Blood was
removed from the pulmonary artery into syringes containing
3.8% sodium citrate (1:10 ratio) for whole blood aggregometry
and platelet-rich plasma (PRP) preparation. Iliac arteries were
removed and prepared for isometric tension studies. Rats were
used to study the effects of succinobucol on platelet aggregation
ex vivo.
Platelet aggregometry
Impedance aggregometry was studied using a Chrono-log, Model
590 aggregometer and responses recorded on a dual-channel chart
recorder. Blood (500 µL) was diluted 50:50 in 0.9% saline and
warmed for 5 minutes at 37°C with stirring. A baseline was
established and aggregation initiated by the addition of collagen
(1–10 µg/mL) or adenosine diphosphate (ADP; 3 × 10−6 M–10−5
M) and followed for approximately 7 minutes. Where succinobu-
col was used, this was added to blood 5 minutes before collagen
or ADP. To prepare PRP, blood was centrifuged at 1200 rpm for
10 minutes and the supernatant collected. Aggregation of PRP
was induced using 20 µg/mL collagen in the presence or absence
of succinobucol. In some experiments, whole blood was exposed
to the superoxide anion generating system xanthine (added at
10−4 M) and xanthine oxidase (6 mU/mL). This was incubated
with the blood for 10 minutes at 37°C before addition of succi-
nobucol and, 5 minutes later, 5 µg/mL collagen. The incubation
periods and the doses of succinobucol, xanthine, and xanthine
oxidase used were based on our previous studies [6,18].
Platelet lipid peroxidation levels (TBARS)
Washed platelets were prepared from rabbit PRP by adding 5 mL
of PRP to 7 mL of washing buffer (NaCl 140 mM, KCl 0.5 mM,
trisodium citrate 12 mM, glucose 10 mM, and saccharose 12.5
mM; pH 6) and centrifuging at 1500 g for 10 minutes. The
platelet pellet was subjected to two repeated washes and resus-
pended in 2 mL Krebs’ solution. Protein concentration in the
samples was determined against a bovine serum albumin (BSA)
standard curve using the Bradford method. The suspension was
divided into two with one tube treated with xanthine (10−4 M) and
xanthine oxidase (6 mU/mL), and the other with X/XO plus 10−5
M succinobucol. After incubation at 37°C for 15 minutes, sam-
ples were centrifuged at 2000 g for 10 minutes and the super-
natant discarded. Platelet pellet proteins were precipitated with
10% (v/v) tricholoroacetic acid (TCA) at 37°C for 15 minutes and
the supernatant was analyzed for the presence of thiobarbituric
acid (TBA) reactive substances (TBARS). Briefly, the supernatant
was mixed with 200 μl of TBA (0.67% w/v) and incubated at 100°
C for 10 minutes then cooled, TBARS were quantified against a
malondialdehyde (MDA) standard curve (0–20 µM). Each stan-
dard was reacted with 200 µl of TBA, followed by incubation at
100°C for 10 minutes. The absorbance of standards and samples
was measured concurrently at a wavelength of 544 nm in a
FLUOstar OPTIMA microplate reader (BMG Labtech,
Germany) and results were quantified as nmol MDA per mg of
platelet protein.
Wire myography
Rabbit iliac artery rings from NZW rabbits were cleaned of
surrounding connective tissue and the endothelium was removed
using forceps. Rings of 2–3 mm were mounted in a small artery
wire myograph (Danish Myotec) in Krebs’ solution containing (in
mM): 118 NaCl, 25 NaHCO3, 4.7 KCl, 1.2 KH2PO4, 1 MgSO4,
2.5 CaCl2, 11 glucose at 37°C, and continuously gassed with 95%
O2 5% CO2. An optimum resting tension of 3 g was applied and
rings were equilibrated and sensitized to two additions of 40 mM
KCl solution. All rings then received an excess of xanthine (10−4
M) and either vehicle or succinobucol (10−4 M or 10−5 M). Ten
minutes later rings were contracted by the addition of 1 µM
phenylephrine, and once the level of artery tone had stabilized,
XO was added at 3, 6, and 9 mU/mL with 10 minutes between
additions. Successful endothelial denudation was measured as a
lack of relaxation (<10% of PE-induced tone) to addition of 10−6
M ACh.
Effects on platelet aggregation ex vivo
Male SD (250–310 g) rats were induced with 3% isoflurane in
oxygen and maintained throughout the procedure on 1–1.5% iso-
flurane via a face mask. Level of anesthesia was monitored and
once the limb withdrawal reflex was lost, a mid-line incision was
made over the neck and the carotid artery and jugular vein were
isolated and cannulated with polyethylene cannulae (Harvard
Apparatus, Kent, UK) filled with heparinized saline. The carotid
cannula was connected to a pressure transducer and data acquisi-
tion system (Bio-Pac Student Lab Pro, BioPac Systems, Norfolk,
UK). The right jugular vein was used for administration of succi-
nobucol. Succinobucol was prepared in ethanol at a concentration
of 10−2 M and diluted in 0.9% saline. Rats received injections of
50, 100, and 150 mg/kg of succinobucol at 15-minute intervals.
From the experimental recordings, mean arterial blood pressure
(MAP) and heart rate was calculated 1, 10, and 15 minutes after
each dose of drug. At the end of the experiment, blood was
collected from the cannula and ex vivo platelet aggregation in
response to collagen was measured by impedance aggregometry.
Control animals received injection of equivalent volumes of etha-
nol/saline vehicle and blood was removed at the same point after
the experiment to measure platelet aggregation.
Materials
Collagen and ADP were from Chronolog, Labmedics Ltd,
Manchester, UK. ADP was dissolved in distilled water to prepare
a stock solution of 10−3 M. All other chemicals were from Sigma-
Aldrich, Poole, Dorset. Succinobucol (previously AGI-1067), the
monosuccinic acid ester of probucol, was synthesized by esterifi-
cation of probucol. The identity of the product was confirmed by
NMR spectroscopy and purity was in excess of 99% [6].
Succinobucol is metabolically stable and no significant active
metabolites are formed in vivo [19]. Xanthine was dissolved in
1 M NaOH solution and sonicated until clear.
Statistical analysis
Data were tested for normality using Kolmogorov–Smirnov test
and all variables were normally distributed. Data are expressed as
mean ± SEM, where n is the number of animals used to supply
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blood or arteries used in the experiments. All statistical analyses
were performed using GraphPad Prism 5.0 (La Jolla, CA, USA).
Differences in platelet aggregation in whole blood and PRP and
platelet lipid peroxidation levels were analyzed using a Student’s
paired t-test. Myography data, in vivo measurements of HR and
MAP, and ex vivo measurements of platelet aggregation were
analyzed by one-way ANOVA with Dunnett’s post hoc test. The
value of p < 0.05 was considered statistically significant in all
cases.
Results
Effect of succinobucol on platelet aggregation
In whole blood, both collagen and ADP caused a dose-dependent
increase in impedance although collagen caused more platelet aggre-
gation within the dose range studied (data not shown). Based on these
preliminary experiments, 5 µg/mL collagen and 5 × 10−6 M ADP
were selected for all further experiments. All three concentrations of
succinobucol caused a significant inhibition of platelet aggregation in
response to collagen (Figure 1A). Baseline impedance in response to
collagen and the value used to calculate percentage reductions was
15.4 ± 2.1 Ω (n = 12). Succinobucol also caused a significant reduc-
tion in aggregation in response to ADP (Figure 1B). Baseline impe-
dance in response to ADP and the value used to calculate percentage
reductions was 5.2 ± 0.4 Ω (n = 10). In PRP, addition of collagen at
concentrations up to 10 µg/mL resulted in very low changes in impe-
dance (2.4 ± 0.5 Ω with collagen 5 µg/mL and 3.8 ± 0.3 Ω with
collagen 10 µg/mL; n = 4) which were insufficient to study an
inhibitory effect of succinobucol on platelet aggregation.
Consequently, a higher concentration of collagen was used in PRP
but succinobucol maintained its ability to significantly reduce aggre-
gation at all three concentrations studied (Figure 1C).
Exposure of rabbit blood to superoxide generated by the com-
bination of X/XO led to an increase in collagen-induced aggrega-
tion compared to control (Figure 2). Preincubating the blood with
succinobucol caused a dose-dependent reversal of the effects of
X/XO and an overall reduction in aggregation compared to col-
lagen alone (Figure 2).
In washed platelets under control conditions, TBARS mea-
sured as nmol of MDA per mg of platelet protein were below
the level of detection. Incubation with a combination of X/XO
(10−4 M xanthine and 6 mU/mL xanthine oxidase) for 15 minutes
resulted in an increase in TBARS (21.16 3.13; n = 4) and there
was a non-significant trend towards a reduction in TBARS with
the addition of 10−5 M succinobucol (12.15 ± 3.26; n = 4; p >
0.05 vs. X/XO alone).
Wire myography
In denuded rabbit iliac artery rings incubated with xanthine and
preconstricted with phenylephrine, addition of three separate con-
centrations of XO caused a dose-dependent relaxation which
peaked at around 45% loss of the induced tone (Figure 3). Both
concentrations of succinobucol significantly attenuated the relaxa-
tion to X/XO.
Effect on platelet aggregation ex vivo
Intravenous injection of succinobucol at 50, 100, and 150 mg/kg
had no significant effect on either heart rate or MAP (Figure 4A
and B). No other unexpected effects were seen and all 10 rats (5
control animals and 5 experimental animals) survived until the
end of the procedure. Blood which was removed 15 minutes after
the final injection of succinobucol showed significantly less
aggregation in response to collagen at both 5 µg/mL and 20 µg/
mL (Figure 4C).
Figure 1. (A) Succinobucol caused a dose-dependent reduction in col-
lagen-induced platelet aggregation in rabbit whole blood. Aggregation
was measured by impedance aggregometry and values in the presence of
succinobucol are expressed as a percentage of the average value of at least
three determinations of impedance in the presence of collagen alone (n =
6; p < 0.05 vs. control). (B) Succinobucol also caused a significant
reduction in whole blood aggregation in response to ADP (n = 10; p <
0.05 vs. control). (C) In rabbit platelet-rich plasma, succinobucol also
caused a dose-dependent reduction in aggregation compared to collagen
alone (n = 5; p < 0.05 vs. control).
Figure 2. Addition of the superoxide generating system xanthine and
xanthine oxidase (X/XO) caused a significant increase in collagen-
induced aggregation of rabbit whole blood. Succinobucol reversed this
increase and in fact lowered aggregation below the value observed with
collagen alone (n = 5; p < 0.05 vs. control).
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Discussion
In this study, we have demonstrated that succinobucol exerts an
antiplatelet effect in rabbit blood against two different aggregating
agents and that it can counteract the activity of ROS in promoting
aggregation and modulating vascular tone. In addition, in vivo
administration of succinobucol had an anti-aggregatory effect on
platelets ex vivo without any effects on MAP or heart rate. We
suggest that antioxidant or free-radical scavenging activity may
underlie the antiplatelet activity of succinobucol.
A previous study in human blood found an inhibitory effect of
succinobucol on platelet aggregation in PRP in response to ADP
but not collagen [9] at concentrations between 15 and 90 µg/ml.
This equates to a molarity of between 24 and 145 µM which is
consistent with our results using between 10 and 100 µM. The
study by Serebruany measured platelet activation markers by flow
cytometry and reported that reductions in PAR-1 receptors and
GP IIb/IIIa may underlie the antiplatelet effects in their study. The
parent compound probucol also exhibits antioxidant activity [20]
and there is a widespread literature which suggests that such
activity can mediate antiplatelet effects [21–23]. Since succino-
Figure 3. In denuded rabbit iliac arteries preconstricted to phenylephrine,
the superoxide generating system X/XO caused a dose-dependent relaxa-
tion. Addition of succinobucol significantly lowered the relaxation to X/
XO (n = 5; p < 0.05 vs. control at maximum dose of X/XO).
Figure 4. In anaesthetized rats, i.v. injection of three concentrations of succinobucol (50, 100, and 150 mg/kg) with 15 minutes between additions had
no significant effect on either heart rate (A) or MAP (B). However, succinobucol did significantly attenuate ex vivo aggregation of platelets in response
to two concentrations of collagen (C). n = 5; p < 0.05 vs. vehicle-treated animals.
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bucol is also an antioxidant, we speculated whether this activity
could underlie its anti-aggregatory effect.
In order to study this further, we exposed whole blood to the
superoxide generating system xanthine and xanthine oxidase (X/
XO). The concentrations of X/XO used in the current study are
consistent with similar studies [24] and there are many reports in the
literature which demonstrate that ROS derived either from platelets
[25], from damaged red blood cells [26] or from addition of free-
radical generating systems [27], can augment platelet aggregation in
response to stimulating agents such as collagen andADP. In this study,
we found that whole blood aggregated more readily in response to
collagen, suggesting that other cell types present in whole blood may
contribute to platelet aggregation. Other studies have indicated that the
hematocrit can influence aggregation [28] and alcohol can induce
release of ADP from RBCs which can increase platelet aggregation
in whole blood [29]. Interestingly, many of the agents used to activate
platelets such as collagen can themselves induce ROS generation
through arachidonic acid (AA) metabolism [30] and ascorbate, a
scavenger of superoxide, inhibits aggregation and AA release. We
found a significant increase in the aggregation response to collagen
when rabbit platelets were pretreated for 10 minutes with X/XO and
this was reversed in a dose-dependent manner by succinobucol, sug-
gesting that free-radical scavenging was responsible. In a previous
study, we used chemiluminescence (CL) to establish that a combina-
tion of 100 µM xanthine and varying concentrations of XO generated
SOD-inhabitable CL [18] and here we further verified the effect of X/
XO on platelet function by studying lipid peroxidation [23]. Inwashed
rabbit platelets, we found that X/XO significantly increased TBARS
above baseline where the level was below detection. Addition of
succinobucol showed a trend towards lowered TBARS but this was
not significant. However, it provides further evidence that succinobu-
col protects the platelets against oxidant stress.
We also sought to establish the effect of succinobucol on the artery
wall since adhesion of aggregating platelets to areas of damaged
endothelium is critical in vivo in mediating not only pathological
thrombus formation but also in repair and prevention of blood loss.
In preconstricted artery rings, addition of increasing concentrations of
the superoxide generating system X/XO caused an endothelium-inde-
pendent relaxation. In the presence of an intact endothelium, super-
oxide will destroy nitric oxide and induce constriction [31]. However,
some studies have shown that activation of arterial superoxide gen-
erating systems such as NADPH oxidase through addition of the
substrate (NADH) causes relaxation at low concentrations [32]. In
our study, we did not attempt to prevent the conversion of superoxide
into hydrogen peroxide, and, since hydrogen peroxide can induce
vasodilation in denuded arteries [33,34], it may be that the vasodilation
we observed was due to hydrogen peroxide rather than superoxide
itself. Nevertheless, the significant inhibition of the vasodilator
response caused by succinobucol provides further evidence that
scavenging of free radicalsmay be an important effect of succinobucol
in vitro. The significance of this finding is difficult to extrapolate in
vivo but it would be interesting in future to study the effects of platelets
on vascular tone under control conditions and following treatment
with succinobucol.
We also studied the effects of in vivo administration of succinobu-
col on basic cardiovascular parameters and platelet aggregation ex
vivo. Doses of succinobucol up to 150mg/kg had no effect onMAP or
HR in anaesthetized rats. These doses are in line with previous in vivo
studies in animals [2], albeit that treatment was chronic in this study. A
previous study reported raised systolic blood pressure in humans
taking succinobucol chronically [5] but we observed no effect after
acute administration in rats, suggesting that effects on blood pressure
develop over time. Interestingly, acute administration of succinobucol
to rats (up to 150 mg/kg) was sufficient to significantly inhibit platelet
aggregation to collagen when blood was removed 15 minutes later.
This implies that enough succinobucol is retained within the blood to
exert an antiplatelet effect ex vivo or perhaps that the lipophilic drug
enters the platelet or modifies its membrane expression of activation
markers to reduce aggregation. Although pharmacokinetic studies
have established that succinobucol is not a pro-drug of probucol [1],
it would be important to establish plasma concentrations of succino-
bucol in these animals and perhaps also use flowcytometry tomeasure
platelet biomarkers. However, in a study by Serebruany et al. [9], a
daily dose of 300 mg/day was reported to result in an average steady-
state concentration of 30 ± 5 µg/mL in human blood. In all the in vitro
experiments performed here, concentrations between 10−5 and 10−4
M succinobucol were used. When these are converted to µg/ml, based
on a formula weight of approximately 617, it gives a concentration of
between 6.17 and 61.7 µg/mL, a concentration range similar to that
found in human subjects.
Overall, our data suggest that at clinically relevant concentra-
tions succinobucol has an antiplatelet effect in vitro and ex vivo.
This is likely mediated through free-radical scavenging or other
means which protect the platelet from oxidant species.
Conclusions
In conclusion, we have demonstrated an antiplatelet effect of
succinobucol in rabbit whole blood and plasma and that succino-
bucol is able to reverse the effects of oxidant stress on platelet
aggregation and vascular tone. We also show that acute in vivo
administration produces an antiplatelet effect ex vivo.
Succinobucol was originally synthesized as an antiatherogenic
medication and has been studied in phase III trials. However, its
potential has not been realized and although experimental studies,
particularly on its antioxidant and antihyperglycaemic effects
continue, it is unlikely to make an impact as a medicine in
humans (reviewed in [19,35]). New derivatives of succinobucol
have been developed and these may offer advantages over the
parent drug [8]. It would be important to establish the antiplatelet
activity of these compounds during development.
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